0
0

Chapter 56. Treatment of Anxiety Disorders

Jonathan R. T. Davidson, M.D.; Kathryn M. Connor, M.D., M.H.S.; Wei Zhang, M.D., Ph.D.
DOI: 10.1176/appi.books.9781585623860.424275

Sections

Excerpt

Over the past decade and a half, there has been substantial progress in our understanding of the anxiety disorders. Particularly fruitful has been the search to develop new treatments for the six major anxiety disorders: obsessive-compulsive disorder (OCD), panic disorder, social phobia (social anxiety disorder), specific phobia, generalized anxiety disorder (GAD), and posttraumatic stress disorder (PTSD). In this chapter, we review the main findings from double-blind, and some open-label, trials in each disorder. Both short-term and continuation/maintenance treatment studies are included.

Your session has timed out. Please sign back in to continue.
Sign In Your Session has timed out. Please sign back in to continue.
Sign In to Access Full Content
 
Username
Password
Sign in via Athens (What is this?)
Athens is a service for single sign-on which enables access to all of an institution's subscriptions on- or off-site.
Not a subscriber?

Subscribe Now/Learn More

PsychiatryOnline subscription options offer access to the DSM-5 library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.

Need more help? PsychiatryOnline Customer Service may be reached by emailing PsychiatryOnline@psych.org or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).

References

Agid O, Shalev AY, Lerer B, et al: Triiodothyronine augmentation of selective serotonin reuptake inhibitors in posttraumatic stress disorder. J Clin Psychiatry 62:169–173, 2001
[PubMed]
 
Alamy S, Zhang W, Varia I, et al: Escitalopram in specific phobia: results of a placebo-controlled pilot trial. J Psychopharmacol 22:157–161, 2008
[PubMed]
 
Allgulander C: Paroxetine in social anxiety disorder: a randomized placebo-controlled study. Acta Psychiatr Scand 100:193–198, 1999
[PubMed]
 
Allgulander C, Hackett D, Salinas E: Venlafaxine extended release (ER) in the treatment of generalised anxiety disorder: twenty-four-week placebo-controlled dose-ranging study. Br J Psychiatry 179:15–22, 2001
[PubMed]
 
Allgulander C, Dahl AA, Austin C, et al: Efficacy of sertraline in a 12-week trial for generalized anxiety disorder. Am J Psychiatry 161:1642–1649, 2004
[PubMed]
 
Allgulander C, Florea I, Huusom AK: Prevention of relapse in generalized anxiety disorder by escitalopram treatment. Int J Neuropsychopharmacol 9:495–505, 2006
[PubMed]
 
Allgulander C, Hartford J, Russell J, et al: Pharmacotherapy of generalized anxiety disorder: results of duloxetine treatment from a pooled analysis of three clinical trials. Curr Med Res Opin 23:1245–1252, 2007
[PubMed]
 
Alonso J, Angermeyer MC, Bernert S, et al: Sampling and methods of the European Study of the Epidemiology of Mental Disorders (ESEMeD) project. Acta Psychiatr Scand Suppl (420):8–20, 2004
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition. Washington, DC, American Psychiatric Association, 1980
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 3rd Edition, Revised. Washington, DC, American Psychiatric Association, 1987
 
American Psychiatric Association: Diagnostic and Statistical Manual of Mental Disorders, 4th Edition. Washington, DC, American Psychiatric Association, 1994
 
Andersch S, Rosenberg NK, Kullingsjo H, et al: Efficacy and safety of alprazolam, imipramine and placebo in treating panic disorder. A Scandinavian multicenter study. Acta Psychiatr Scand Suppl 365:18–27, 1991
[PubMed]
 
Asakura S, Tajima O, Koyama T: Fluvoxamine treatment of generalized social anxiety disorder in Japan: a randomized double-blind, placebo-controlled study. Int J Neuropsychopharmacol 10:263–274, 2007
[PubMed]
 
Asnis GM, Hameedi FA, Goddard AW, et al: Fluvoxamine in the treatment of panic disorder: a multi-center, double-blind, placebo-controlled study in outpatients. Psychiatry Res 103:1–14, 2001
[PubMed]
 
Baer L, Rauch SL, Ballantine HT Jr, et al: Cingulotomy for intractable obsessive-compulsive disorder. Prospective long-term follow-up of 18 patients. Arch Gen Psychiatry 52:384–392, 1995
[PubMed]
 
Baker DG, Diamond BI, Gillette G, et al: A double-blind, randomized, placebo-controlled, multi-center study of brofaromine in the treatment of post-traumatic stress disorder. Psychopharmacology (Berl) 122:386–389, 1995
[PubMed]
 
Bakish D, Saxena BM, Bowen R, et al: Reversible monoamine oxidase-A inhibitors in panic disorder. Clin Neuropharmacol 16 (suppl 2):S77–S82, 1993
 
Baldwin D, Bobes J, Stein DJ, et al: Paroxetine in social phobia/social anxiety disorder. Randomised, double-blind, placebo-controlled study. Paroxetine Study Group. Br J Psychiatry 175:120–126, 1999
[PubMed]
 
Baldwin DS, Huusom AK, Maehlum E: Escitalopram and paroxetine in the treatment of generalised anxiety disorder: randomised, placebo-controlled, double-blind study. Br J Psychiatry 189:264–272, 2006
[PubMed]
 
Ballenger JC, Davidson JR, Lecrubier Y, et al: Consensus statement on panic disorder from the International Consensus Group on Depression and Anxiety. J Clin Psychiatry 59 (suppl 8):47–54, 1998a
 
Ballenger JC, Wheadon DE, Steiner M, et al: Double-blind, fixed-dose, placebo-controlled study of paroxetine in the treatment of panic disorder. Am J Psychiatry 155:36–42, 1998b
 
Bandelow B, Hajak G, Holzrichter S, et al: Assessing the efficacy of treatments for panic disorder and agoraphobia, I: methodological problems. Int Clin Psychopharmacol 10:83–93, 1995
[PubMed]
 
Barnett SD, Kramer ML, Casat CD, et al: Efficacy of olanzapine in social anxiety disorder: a pilot study. J Psychopharmacol (Oxf) 16:365–368, 2002
[PubMed]
 
Bartzokis G, Lu PH, Turner J, et al: Adjunctive risperidone in the treatment of chronic combat-related posttraumatic stress disorder. Biol Psychiatry 57:474–479, 2005
[PubMed]
 
Beckham JC, Vrana SR, Barefoot JC, et al: Magnitude and duration of cardiovascular responses to anger in Vietnam veterans with and without posttraumatic stress disorder. J Consult Clin Psychol 70:228–234, 2002
[PubMed]
 
Bell J, DeVeaugh-Geiss J: Multicenter trial of a 5-HT antagonist, ondansetron, in social phobia. Paper presented at the 33rd Annual Meeting of the American College of Neuropsychopharmacology, San Juan, Puerto Rico, December 12–16, 1994
 
Bellew KM, McCafferty JP, Iyengar M: Short-term efficacy of paroxetine in generalized anxiety disorder: a double-blind placebo-controlled trial (NR253). Paper presented at the 153rd Annual Meeting of the American Psychiatric Association, Chicago, IL, May 13–18, 2000
 
Benjamin J, Ben-Zion IZ, Karbofsky E, et al: Double-blind placebo-controlled pilot study of paroxetine for specific phobia. Psychopharmacology 149:194–196, 2000
[PubMed]
 
Bergink V, Westenberg HG: Metabotropic glutamate II receptor agonists in panic disorder: a double blind clinical trial with LY354740. Int Clin Psychopharmacol 20:291–293, 2005
[PubMed]
 
Berigan TR: Panic attacks during escalation of mirtazapine. Primary Care Companion to the Journal of Clinical Psychiatry 5:93, 2003
[PubMed]
 
Berlant J, van Kammen DP: Open-label topiramate as primary or adjunctive therapy in chronic civilian posttraumatic stress disorder: a preliminary report. J Clin Psychiatry 63:15–20, 2002
[PubMed]
 
Bertani A, Perna G, Migliarese G, et al: Comparison of the treatment with paroxetine and reboxetine in panic disorder: a randomized, single-blind study. Pharmacopsychiatry 37:206–210, 2004
[PubMed]
 
Bielski RJ, Bose A, Chang CC: A double-blind comparison of escitalopram and paroxetine in the long-term treatment of generalized anxiety disorder. Ann Clin Psychiatry 17:65–69, 2005
[PubMed]
 
Bisson J, Andrew M: Psychological treatment of post-traumatic stress disorder (PTSD). Cochrane Database Syst Rev (2):CD003388, 2005
 
Black DW, Wesner R, Bowers W, et al: A comparison of fluvoxamine, cognitive therapy, and placebo in the treatment of panic disorder. Arch Gen Psychiatry 50:44–50, 1993
[PubMed]
 
Blake DD, Weathers FW, Nagy LM, et al: The development of a clinician-administered PTSD scale. J Trauma Stress 8:75–90, 1995
[PubMed]
 
Bloch MH, Landeros-Weisenberger A, Kelmendi B, et al: A systematic review: antipsychotic augmentation with treatment refractory obsessive-compulsive disorder. Mol Psychiatry 11:622–632, 2006
[PubMed]
 
Blomhoff S, Haug TT, Hellstrom K, et al: Randomised controlled general practice trial of sertraline, exposure therapy and combined treatment in generalised social phobia. Br J Psychiatry 179:23–30, 2001
[PubMed]
 
Bonne O, Shemer Y, Gorali Y, et al: A randomized, double-blind, placebo-controlled study of classical homeopathy in generalized anxiety disorder. J Clin Psychiatry 64:282–287, 2003
[PubMed]
 
Boshuisen ML, Slaap BR, Vester-Blokland ED, et al: The effect of mirtazapine in panic disorder: an open label pilot study with a single-blind placebo run-in period. Int Clin Psychopharmacol 16:363–368, 2001
[PubMed]
 
Boyer W: Serotonin uptake inhibitors are superior to imipramine and alprazolam in alleviating panic attacks: a meta-analysis. Int Clin Psychopharmacol 10:45–49, 1995
[PubMed]
 
Bradley R, Greene J, Russ E, et al: A multidimensional meta-analysis of psychotherapy for PTSD. Am J Psychiatry 162:214–227, 2005
[PubMed]
 
Bradwejn J, Ahokas A, Stein DJ, et al: Venlafaxine extended-release capsules in panic disorder: flexible-dose, double-blind, placebo-controlled study. Br J Psychiatry 187:352–359, 2005
[PubMed]
 
Brady K, Pearlstein T, Asnis GM, et al: Efficacy and safety of sertraline treatment of posttraumatic stress disorder: a randomized controlled trial. JAMA 283:1837–1844, 2000
[PubMed]
 
Brady KT, Sonne S, Anton RF, et al: Sertraline in the treatment of co-occurring alcohol dependence and posttraumatic stress disorder. Alcohol Clin Exp Res 29:395–401, 2005
[PubMed]
 
Braun P, Greenberg D, Dasberg H, et al: Core symptoms of posttraumatic stress disorder unimproved by alprazolam treatment. J Clin Psychiatry 51:236–238, 1990
[PubMed]
 
Brawman-Mintzer O, Knapp RG, Rynn M, et al: Sertraline treatment for generalized anxiety disorder: a randomized, double-blind, placebo-controlled study. J Clin Psychiatry 67:874–881, 2006
[PubMed]
 
Bruscky SB, Caldeira MV, Bueno JR: Clinical trials of sulpiride. Arq Neuropsiquiatr 32:234–239, 1974
[PubMed]
 
Bryant RA, Harvey AG, Dang ST, et al: Treatment of acute stress disorder: a comparison of cognitive-behavioral therapy and supportive counseling. J Consult Clin Psychol 66:862–866, 1998
[PubMed]
 
Bryant RA, Moulds ML, Nixon RV, et al: Cognitive behaviour therapy of acute stress disorder: a four-year follow-up. Behav Res Ther 41:489–494, 2003
[PubMed]
 
Butterfield MI, Becker ME, Connor KM, et al: Olanzapine in the treatment of post-traumatic stress disorder: a pilot study. Int Clin Psychopharmacol 16:197–203, 2001
[PubMed]
 
Bystritsky A, Kerwin L, Eiduson S, et al: A pilot controlled trial of bupropion vs. escitalopram in generalized anxiety disorder (GAD) [abstract]. Neuropsychopharmacology 30 (suppl 1):S101, 2005
 
Cates ME, Bishop MH, Davis LL, et al: Clonazepam for treatment of sleep disturbances associated with combat-related posttraumatic stress disorder. Ann Pharmacother 38:1395–1399, 2004
[PubMed]
 
Chantarujikapong SI, Scherrer JF, Xian H, et al: A twin study of generalized anxiety disorder symptoms, panic disorder symptoms and post-traumatic stress disorder in men. J Nerv Ment Dis 103:133–145, 2001
[PubMed]
 
Charney DS, Woods SW, Goodman WK, et al: Drug treatment of panic disorder: the comparative efficacy of imipramine, alprazolam, and trazodone. J Clin Psychiatry 47:580–586, 1986
[PubMed]
 
Chen A, Zhao Y, Yu X: The clinical study of antianxiety and antidepressive effect of sulpiride. Chin J Neurol Psychiatry 27:220–222, 1994
 
Clark DB, Agras WS: The assessment and treatment of performance anxiety in musicians. Am J Psychiatry 148:598–605, 1991
[PubMed]
 
Clark DM, Ehlers A, McManus F, et al: Cognitive therapy versus fluoxetine in generalized social phobia: a randomized placebo-controlled trial. J Consult Clin Psychol 71:1058–1067, 2003
[PubMed]
 
Clark RD, Canive JM, Calais LA, et al: Divalproex in posttraumatic stress disorder: an open-label clinical trial. J Trauma Stress 12:395–401, 1999
[PubMed]
 
Clomipramine Collaborative Study Group: Clomipramine in the treatment of patients with obsessive-compulsive disorder. Arch Gen Psychiatry 48:730–738, 1991
 
Clum GA, Surls R: A meta-analysis of treatments for panic disorder. J Consult Clin Psychol 61:317–326, 1993
[PubMed]
 
Cohn JB, Bowden CL, Fisher JG, et al: Double-blind comparison of buspirone and clorazepate in anxious outpatients. Am J Med 80:10–16, 1986
[PubMed]
 
Compton SN, Grant PJ, Chrisman AK, et al: Sertraline in children and adolescents with social anxiety disorder: an open trial. J Am Acad Child Adolesc Psychiatry 40:564–571, 2001
[PubMed]
 
Connor KM, Davidson JRT: SPRINT: a brief global assessment of post-traumatic stress disorder. Int Clin Psychopharmacol 16:279–284, 2001
[PubMed]
 
Connor KM, Davidson JRT: A placebo-controlled study of kava kava in generalized anxiety disorder. Int Clin Psychopharmacol 17:185–188, 2002
[PubMed]
 
Connor KM, Davidson JR, Potts NL, et al: Discontinuation of clonazepam in the treatment of social phobia. J Clin Psychopharmacol 18:373–378, 1998
[PubMed]
 
Connor KM, Sutherland SM, Tupler LA, et al: Fluoxetine in post-traumatic stress disorder. Randomised, double-blind study. Br J Psychiatry 175:17–22, 1999
[PubMed]
 
Connor KM, Davidson JRT, Churchill EL, et al: Psychometric properties of the Social Phobia Inventory (SPIN). A new self-rating scale. Br J Psychiatry 176:379–386, 2000
[PubMed]
 
Cottraux J, Mollard E, Bouvard M, et al: Exposure therapy, fluvoxamine, or combination treatment in obsessive-compulsive disorder: one-year follow-up. Psychiatry Res 49:63–75, 1993
[PubMed]
 
Crockett BA, Davidson JRT, Churchill LE: Treatment of obsessive-compulsive disorder with clonazepam and sertraline versus placebo and sertraline. Paper presented at the 39th Annual Meeting of the New Clinical Drug Evaluation Unit, Boca Raton, FL, June 1, 1999
 
Cross-National Collaborative Panic Study: Drug treatment of panic disorder. Comparative efficacy of alprazolam, imipramine, and placebo. Br J Psychiatry 160:191–202, 1992
 
Davidson JRT: The long-term treatment of panic disorder. J Clin Psychiatry 59 (suppl 8):17–21, 1998
 
Davidson JRT, Moroz G: Pivotal studies of clonazepam in panic disorder. Psychopharmacol Bull 34:169–174, 1998
[PubMed]
 
Davidson JRT, Kudler H, Smith R, et al: Treatment of posttraumatic stress disorder with amitriptyline and placebo. Arch Gen Psychiatry 47:259–266, 1990
[PubMed]
 
Davidson JRT, Hughes DL, George LK, et al: The epidemiology of social phobia: findings from the Duke Epidemiological Catchment Area Study. Psychol Med 23:709–718, 1993
[PubMed]
 
Davidson JRT, Tupler LA, Potts NL: Treatment of social phobia with benzodiazepines. J Clin Psychiatry 55 (suppl):28–32, 1994
 
Davidson JRT, Book SW, Colket JT, et al: Assessment of a new self-rating scale for post-traumatic stress disorder. Psychol Med 27:153–160, 1997a
 
Davidson JRT, Miner CM, DeVeaugh-Geiss J, et al: The Brief Social Phobia Scale: a psychometric evaluation. Psychol Med 27:161–166, 1997b
 
Davidson JRT, Weisler RH, Malik M, et al: Fluvoxamine in civilians with posttraumatic stress disorder. J Clin Psychopharmacol 18:93–95, 1998
[PubMed]
 
Davidson JRT, DuPont RL, Hedges D, et al: Efficacy, safety, and tolerability of venlafaxine extended release and buspirone in outpatients with generalized anxiety disorder. J Clin Psychiatry 60:528–535, 1999
[PubMed]
 
Davidson JRT, Pearlstein T, Londborg P, et al: Efficacy of sertraline in preventing relapse of posttraumatic stress disorder: results of a 28-week double-blind, placebo-controlled study. Am J Psychiatry 158:1974–1981, 2001
[PubMed]
 
Davidson JRT, Landerman LR, Farfel GM, et al: Characterizing the effects of sertraline in post-traumatic stress disorder. Psychol Med 32:661–670, 2002
[PubMed]
 
Davidson JRT, Weisler RH, Butterfield MI, et al: Mirtazapine vs. placebo in posttraumatic stress disorder: a pilot trial. Biol Psychiatry 53:188–191, 2003
[PubMed]
 
Davidson JRT, Bose A, Korotzer A, et al: Escitalopram in the treatment of generalized anxiety disorder: double-blind, placebo controlled, flexible-dose study. Depress Anxiety 19:234–240, 2004a
 
Davidson JRT, Foa EB, Huppert JD, et al: Fluoxetine, comprehensive cognitive behavioral therapy (CCBT) and placebo in generalized social phobia. Arch Gen Psychiatry 61:1005–1013, 2004b
 
Davidson JRT, Yaryura-Tobias J, DuPont R, et al: Fluvoxamine-controlled release formulation for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:118–225, 2004c
 
Davidson JRT, Connor KM, Hertzberg MA, et al: Maintenance therapy with fluoxetine in posttraumatic stress disorder: a placebo-controlled discontinuation study. J Clin Psychopharmacol 25:166–169, 2005
[PubMed]
 
Davidson JRT, Baldwin D, Stein DJ, et al: Treatment of posttraumatic stress disorder with venlafaxine extended release: a 6-month randomized controlled trial. Arch Gen Psychiatry 63:1158–1165, 2006a
 
Davidson JRT, Rothbaum BO, Tucker P, et al: Venlafaxine extended release in posttraumatic stress disorder: a sertraline- and placebo-controlled study. J Clin Psychopharmacol 26:259–267, 2006b
 
Davidson JRT, Brady K, Mellman TA, et al: The efficacy and tolerability of tiagabine in adult patients with post-traumatic stress disorder. J Clin Psychopharmacol 27:85–88, 2007
[PubMed]
 
Davis LL, Jewell ME, Ambrose S, et al: A placebo-controlled study of nefazodone for the treatment of chronic posttraumatic stress disorder: a preliminary study. J Clin Psychopharmacol 24:291–297, 2004
[PubMed]
 
Den Boer JA, Westenberg HG: Effect of a serotonin and noradrenaline uptake inhibitor in panic disorder; a double-blind comparative study with fluvoxamine and maprotiline. Int Clin Psychopharmacol 3:59–74, 1988
 
Denys D, van Nieuwerburgh F, Deforce D, et al: Prediction of response to paroxetine and venlafaxine by serotonin-related genes in obsessive-compulsive disorder in a randomized, double-blind trial. J Clin Psychiatry 68:747–753, 2007
[PubMed]
 
Eddy K, Dutra L, Bradley R, et al: A multidimensional meta-analysis of psychotherapy and pharmacotherapy for obsessive-compulsive disorder. Clin Psychol Rev 24:1–30, 2004
 
Eidelman I, Seedat S, Stein DJ: Risperidone in the treatment of acute stress disorder in physically traumatized in-patients. Depress Anxiety 11:187–188, 2000
[PubMed]
 
Emmanuel NP, Lydiard RB, Ballenger JC: Treatment of social phobia with bupropion. J Clin Psychopharmacol 11:276–277, 1991
[PubMed]
 
Enkelmann R: Alprazolam versus buspirone in the treatment of outpatients with generalized anxiety disorder. Psychopharmacology (Berl) 105:428–432, 1991
[PubMed]
 
Fahlen T, Nilsson HL, Borg K, et al: Social phobia: the clinical efficacy and tolerability of the monoamine oxidase-A and serotonin uptake inhibitor brofaromine. A double-blind placebo-controlled study. Acta Psychiatr Scand 92:351–358, 1995
[PubMed]
 
Fahy TJ, O'Rourke D, Brophy J, et al: The Galway Study of Panic Disorder, I: clomipramine and lofepramine in DSM-III-R panic disorder. A placebo controlled trial. J Affect Disord 25:63–75, 1992
[PubMed]
 
Fallon BA, Campeas R, Schneier FR, et al: Open trial of intravenous clomipramine in five treatment-refractory patients with obsessive-compulsive disorder. J Neuropsychiatry Clin Neurosci 4:70–75, 1992
[PubMed]
 
Fedoroff I, Taylor S: Psychological and pharmacological treatments of social phobia: a meta-analysis. J Clin Psychopharmacol 21:311–324, 2001
[PubMed]
 
Feltner DE, Crockatt JG, Dubovsky SJ, et al: A randomized, double-blind, placebo-controlled, fixed-dose, multicenter study of pregabalin in patients with generalized anxiety disorder. J Clin Psychopharmacol 23:240–249, 2003
[PubMed]
 
Ferguson JM, Khan A, Mangano R, et al: Relapse prevention of panic disorder in adult outpatient responders to treatment with venlafaxine extended release. J Clin Psychiatry 68:58–68, 2007
[PubMed]
 
Fernandez-Cordoba E, Lopez-Ibor JA: La monoclorimipramina en enfermos psiquitricos resistentes a otrostratiamentos. Actas Luso-Espanolas de Neurologia, y Psiquiatria Ciencias Afines 26:119–147, 1967
[PubMed]
 
Ferreri M, Hantouche EG: Recent clinical trials of hydroxyzine in generalized anxiety disorder. Acta Psychiatr Scand Suppl 393:102–108, 1998
[PubMed]
 
Fesler FA: Valproate in combat-related posttraumatic stress disorder. J Clin Psychiatry 52:361–364, 1991
[PubMed]
 
Fineberg NA, Sivakumaran T, Roberts A, et al: Adding quetiapine to SRI in treatment-resistant obsessive-compulsive disorder: a randomized controlled treatment study. Int Clin Psychopharmacol 20:223–226, 2005
[PubMed]
 
Fineberg NA, Tonnoir B, Lemming O, et al: Escitalopram prevents relapse of obsessive-compulsive disorder. Eur Neuropsychopharmacol 17:430–439, 2007
[PubMed]
 
Flament MF, Rapoport JL, Berg CJ, et al: Clomipramine treatment of childhood obsessive-compulsive disorder. A double-blind controlled study. Arch Gen Psychiatry 42:977–983, 1985
[PubMed]
 
Foa EB, Liebowitz MR, Kozak MJ, et al: Randomized, placebo-controlled trial of exposure and ritual prevention, clomipramine, and their combination in the treatment of obsessive-compulsive disorder. Am J Psychiatry 162:151–161, 2005
[PubMed]
 
Fontaine R, Beaudry P, Beauclair L, et al: Comparison of withdrawal of buspirone and diazepam: a placebo controlled study. Prog Neuropsychopharmacol Biol Psychiatry 11:189–197, 1987
[PubMed]
 
Friedman MJ, Marmar CR, Baker DG, et al: Randomized double-blind comparison of sertraline and placebo for posttraumatic stress disorder in a Department of Veterans Affairs setting. J Clin Psychiatry 68:711–720, 2007
[PubMed]
 
Fux M, Levine J, Aviv A, et al: Inositol treatment of obsessive-compulsive disorder. Am J Psychiatry 153:1219–1221, 1996
[PubMed]
 
Gelenberg AJ, Lydiard RB, Rudolph RL, et al: Efficacy of venlafaxine extended-release capsules in nondepressed outpatients with generalized anxiety disorder: a 6-month randomized controlled trial. JAMA 283:3082–3088, 2000
[PubMed]
 
Gelernter CS, Uhde TW, Cimbolic P, et al: Cognitive-behavioral and pharmacological treatments of social phobia. A controlled study. Arch Gen Psychiatry 48:938–945, 1991
[PubMed]
 
Gelpin E, Bonne O, Peri T, et al: Treatment of recent trauma survivors with benzodiazepines: a prospective study. J Clin Psychiatry 57:390–394, 1996
[PubMed]
 
Goddard AW, Brouette T, Almai A, et al: Early coadministration of clonazepam with sertraline for panic disorder. Arch Gen Psychiatry 58:681–686, 2001
[PubMed]
 
Goisman RM, Allsworth J, Rogers MP, et al: Simple phobia as a comorbid anxiety disorder. Depress Anxiety 7:105–112, 1998
[PubMed]
 
Goldberg DP, Lecrubier Y: Form and frequency of mental disorders across centers, in Mental Illness in General Health Care: An International Study. Edited by Üstürn TB, Sartorius N. New York, Wiley, 1995, pp 323–334
 
Goodman WK, Price LH, Rasmussen SA, et al: The Yale-Brown Obsessive Compulsive Scale, II: validity. Arch Gen Psychiatry 46:1012–1016, 1989
[PubMed]
 
Goodman WK, Bose A, Wang Q: Treatment of generalized anxiety disorder with escitalopram: pooled results from double-blind, placebo-controlled trials. J Affect Disord 87:161–167, 2005
[PubMed]
 
Goodnick PJ, Puig A, DeVane CL, et al: Mirtazapine in major depression with comorbid generalized anxiety disorder. J Clin Psychiatry 60:446–448, 1999
[PubMed]
 
Greenberg BD, Malone DA, Friehs GM, et al: Three-year outcomes in deep brain stimulation for highly resistant obsessive-compulsive disorder. Neuropsychopharmacology 31:2384–2393, 2006
[PubMed]
 
Greenberg PE, Sisitsky T, Kessler RC, et al: The economic burden of anxiety disorders in the 1990s. J Clin Psychiatry 60:427–435, 1999
[PubMed]
 
Greenblatt DJ, Shader RI, Abernethy DR: Drug therapy. Current status of benzodiazepines. N Engl J Med 309:410–416, 1983
[PubMed]
 
Greist JH, Jefferson JW: Pharmacotherapy for obsessive-compulsive disorder. Br J Psychiatry Suppl (35):64–70, 1998
 
Greist JH, Chouinard G, DuBoff E, et al: Double-blind parallel comparison of three dosages of sertraline and placebo in outpatients with obsessive-compulsive disorder. Arch Gen Psychiatry 52:289–295, 1995a
 
Greist JH, Jefferson JW, Kobak KA, et al: Efficacy and tolerability of serotonin transport inhibitors in obsessive-compulsive disorder. A meta-analysis. Arch Gen Psychiatry 52:53–60, 1995b
 
Hamilton M: The assessment of anxiety states by rating. Br J Med Psychol 32:50–55, 1959
[PubMed]
 
Hamilton M: A rating scale for depression. J Neurol Neurosurg Psychiatry 23:56–62, 1960
[PubMed]
 
Hamner MB, Faldowski RA, Ulmer HG, et al: Adjunctive risperidone treatment in post-traumatic stress disorder: a preliminary controlled trial of effects on comorbid psychotic symptoms. Int Clin Psychopharmacol 18:1–8, 2003
[PubMed]
 
Hariri AR, Drabant EM, Munoz KE, et al: A susceptibility gene for affective disorders and the response of the human amygdala. Arch Gen Psychiatry 62:145–152, 2005
 
Haug TT, Hellstrom K, Blomhoff S, et al: The treatment of social phobia in general practice: is exposure therapy feasible? Fam Pract 17:114–118, 2000
[PubMed]
 
Haug TT, Blomoff S, Hellstrom K, et al: Exposure therapy and sertraline in social phobia: 1-year follow-up of a randomized controlled trial. Br J Psychiatry 182:312–318, 2003
[PubMed]
 
Heimberg RG, Liebowitz MR, Hope DA, et al: Cognitive behavioral group therapy vs phenelzine therapy for social phobia: 12-week outcome. Arch Gen Psychiatry 55:1133–1141, 1998
[PubMed]
 
Hertzberg MA, Butterfield MI, Feldman ME, et al: A preliminary study of lamotrigine for the treatment of posttraumatic stress disorder. Biol Psychiatry 45:1226–1229, 1999
[PubMed]
 
Hettema JM, Neale MC, Kendler KS: A review and meta-analysis of the genetic epidemiology of anxiety disorders. Am J Psychiatry 158:1568–1578, 2001
[PubMed]
 
Hettema JM, Neale MC, Myers JM, et al: A population-based twin study of the relationship between neuroticism and internalizing disorders. Am J Psychiatry 163:857–864, 2006
[PubMed]
 
Hidalgo R, Hertzberg MA, Mellman T, et al: Nefazodone in post-traumatic stress disorder: results from six open-label trials. Int Clin Psychopharmacol 14:61–68, 1999
[PubMed]
 
Hidalgo RB, Tupler LA, Davidson JRT: An effect-size analysis of pharmacological treatments for generalized anxiety disorder. J Psychopharmacol 21:864–872, 2007
[PubMed]
 
Hoehn-Saric R, McLeod DR, Zimmerli WD: Differential effects of alprazolam and imipramine in generalized anxiety disorder: somatic versus psychic symptoms. J Clin Psychiatry 49:293–301, 1988
[PubMed]
 
Hofmann SG: Cognitive mediation of change in social phobia. J Consult Clin Psychol 72:393–399, 2004
[PubMed]
 
Hofmann SG, Meuret AE, Smits JA, et al: Augmentation of exposure therapy with D-cycloserine for social anxiety disorder. Arch Gen Psychiatry 63:298–304, 2006
[PubMed]
 
Hollander E, Stein DJ, Kwon JH, et al: Psychosocial and economic costs of obsessive-compulsive disorder. CNS Spectr 2:16–25, 1997
 
Hollifield M, Thompson PM, Ruiz JE, et al: Potential effectiveness and safety of olanzapine in refractory panic disorder. Depress Anxiety 21:33–40, 2005
[PubMed]
 
Horowitz M, Wilner N, Alvarez W: Impact of Event Scale: a measure of subjective stress. Psychosom Med 41:209–218, 1979
[PubMed]
 
International Multicenter Clinical Trial Group on Moclobemide in Social Phobia: Moclobemide in social phobia. A double-blind, placebo-controlled clinical study. Eur Arch Psychiatry Clin Neurosci 247:71–80, 1997
 
Jacobs RJ, Davidson JR, Gupta S, et al: The effects of clonazepam on quality of life and work productivity in panic disorder. Am J Manag Care 3:1187–1196, 1997
[PubMed]
 
Jacobs-Rebhun S, Schnurr PP, Friedman MJ, et al: Posttraumatic stress disorder and sleep difficulty. Am J Psychiatry 157:1525–1526, 2000
[PubMed]
 
Jenike MA, Baer L, Ballantine T, et al: Cingulotomy for refractory obsessive-compulsive disorder. A long-term follow-up of 33 patients. Arch Gen Psychiatry 48:548–555, 1991
[PubMed]
 
Jobson KO, Davidson JR, Lydiard RB, et al: Algorithm for the treatment of panic disorder with agoraphobia. Psychopharmacol Bull 31:483–485, 1995
[PubMed]
 
Johnstone EC, Owens DG, Frith CD, et al: Neurotic illness and its response to anxiolytic and antidepressant treatment. Psychol Med 10:321–328, 1980
[PubMed]
 
Kaplan Z, Amir M, Swartz M, et al: Inositol treatment of post-traumatic stress disorder. Anxiety 2:51–52, 1996
[PubMed]
 
Kasper S, Stein DJ, Loft H, et al: Escitalopram in the treatment of social anxiety disorder: randomised, placebo-controlled, flexible-dosage study. Br J Psychiatry 186:222–226, 2005
[PubMed]
 
Katschnig H, Amering M, Stolk JM, et al: Long-term follow-up after a drug trial for panic disorder. Br J Psychiatry 167:487–494, 1995
[PubMed]
 
Katz RJ, Lott MH, Arbus P, et al: Pharmacotherapy of post-traumatic stress disorder with a novel psychotropic. Anxiety 1:169–174, 1994
[PubMed]
 
Katzelnick DJ, Kobak KA, Greist JH, et al: Sertraline for social phobia: a double-blind, placebo-controlled crossover study. Am J Psychiatry 152:1368–1371, 1995
[PubMed]
 
Keck PE Jr, McElroy SL, Tugrul KC, et al: Antiepileptic drugs for the treatment of panic disorder. Neuropsychobiology 27:150–153, 1993
[PubMed]
 
Kessler RC, Sonnega A, Bromet E, et al: Posttraumatic stress disorder in the National Comorbidity Survey. Arch Gen Psychiatry 52:1048–1060, 1995
[PubMed]
 
Kessler RC, Berglund P, Demler O, et al: Lifetime prevalence and age-of-onset distributions of DSM-IV disorders in the National Comorbidity Survey Replication. Arch Gen Psychiatry 62:593–602, 2005a
 
Kessler RC, Chiu WT, Demler O, et al: Prevalence, severity, and comorbidity of 12-month DSM-IV disorders in the National Comorbidity Survey Replication.[see comment]. Arch Gen Psychiatry 62:617–627, 2005b
 
Klesmer J, Sarcevic A, Fomari V: Panic attacks during discontinuation of mirtazapine. Can J Psychiatry 45:570–571, 2000
[PubMed]
 
Kobak KA, Greist JH, Jefferson JW, et al: Fluoxetine in social phobia: a double-blind, placebo-controlled pilot study. J Clin Psychopharmacol 22:257–262, 2002
[PubMed]
 
Kobak KA, Taylor LV, Bystritsky A, et al: St. John's wort versus placebo in obsessive-compulsive disorder: results from a double-blind study. Int Clin Psychopharmacol 20:299–304, 2005
[PubMed]
 
Koenen KC, Fu QJ, Ertel K, et al: Common genetic liability to major depression and posttraumatic stress disorder in men. J Affect Disord 105:109–115, 2008
[PubMed]
 
Koran LM, McElroy SL, Davidson JR, et al: Fluvoxamine versus clomipramine for obsessive-compulsive disorder: a double-blind comparison. J Clin Psychopharmacol 16:121–129, 1996
[PubMed]
 
Koran LM, Sallee FR, Pallanti S: Rapid benefit of intravenous pulse loading of clomipramine in obsessive-compulsive disorder. Am J Psychiatry 154:396–401, 1997
[PubMed]
 
Kosten TR, Frank JB, Dan E, et al: Pharmacotherapy for posttraumatic stress disorder using phenelzine or imipramine. J Nerv Ment Dis 179:366–370, 1991
[PubMed]
 
Kruger MB, Dahl AA: The efficacy and safety of moclobemide compared to clomipramine in the treatment of panic disorder. Eur Arch Psychiatry Clin Neurosci 249 (suppl 1):S19–S24, 1999
 
Lader M, Scotto JC: A multicentre double-blind comparison of hydroxyzine, buspirone and placebo in patients with generalized anxiety disorder. Psychopharmacology (Berl) 139:402–406, 1998
[PubMed]
 
Lader M, Stender K, Burger V, et al: Efficacy and tolerability of escitalopram in 12- and 24-week treatment of social anxiety disorder: randomised, double-blind, placebo-controlled, fixed-dose study. Depress Anxiety 19:241–248, 2004
[PubMed]
 
Lecrubier Y, Judge R: Long-term evaluation of paroxetine, clomipramine and placebo in panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:153–160, 1997
[PubMed]
 
Lecrubier Y, Bakker A, Dunbar G, et al: A comparison of paroxetine, clomipramine and placebo in the treatment of panic disorder. Collaborative Paroxetine Panic Study Investigators. Acta Psychiatr Scand 95:145–152, 1997
[PubMed]
 
Leonard H, Swedo S, Rapoport JL, et al: Treatment of childhood obsessive compulsive disorder with clomipramine and desmethylimipramine: a double-blind crossover comparison. Psychopharmacol Bull 24:93–95, 1988
[PubMed]
 
Lepola UM, Wade AG, Leinonen EV, et al: A controlled, prospective, 1-year trial of citalopram in the treatment of panic disorder. J Clin Psychiatry 59:528–534, 1998
[PubMed]
 
Lesser IM, Lydiard RB, Antal E, et al: Alprazolam plasma concentrations and treatment response in panic disorder and agoraphobia. Am J Psychiatry 149:1556–1562, 1992
[PubMed]
 
Liebowitz MR: Social phobia. Mod Probl Pharmacopsychiatry 22:141–173, 1987
[PubMed]
 
Liebowitz MR, Schneier F, Campeas R, et al: Phenelzine vs atenolol in social phobia. A placebo-controlled comparison. Arch Gen Psychiatry 49:290–300, 1992
[PubMed]
 
Liebowitz MR, Turner SM, Piacentini J, et al: Fluoxetine in children and adolescents with OCD: a placebo-controlled trial. J Am Acad Child Adolesc Psychiatry 41:1431–1438, 2002
[PubMed]
 
Liebowitz MR, DeMartinis NA, Weihs K, et al: Efficacy of sertraline in severe generalized social anxiety disorder: results of a double-blind, placebo-controlled study. J Clin Psychiatry 64:785–792, 2003
[PubMed]
 
Liebowitz MR, Mangano RM, Bradwejn J, et al: A randomized controlled trial of venlafaxine extended release in generalized social anxiety disorder. J Clin Psychiatry 66:238–247, 2005
[PubMed]
 
Lipper S, Davidson JR, Grady TA, et al: Preliminary study of carbamazepine in post-traumatic stress disorder. Psychosomatics 27:849–854, 1986
[PubMed]
 
Lipsitz JD, Mannuzza S, Klein DF, et al: Specific phobia 10–16 years after treatment. Depress Anxiety 10:105–111, 1999
[PubMed]
 
Llorca PM, Spadone C, Sol O, et al: Efficacy and safety of hydroxyzine in the treatment of generalized anxiety disorder: a 3-month double-blind study [see comment]. J Clin Psychiatry 63:1020–1027, 2002
[PubMed]
 
Loerch B, Graf-Morgenstern M, Hautzinger M, et al: Randomised placebo-controlled trial of moclobemide, cognitive-behavioural therapy and their combination in panic disorder with agoraphobia. Br J Psychiatry 174:205–212, 1999
[PubMed]
 
Londborg PD, Wolkow R, Smith WT, et al: Sertraline in the treatment of panic disorder. A multi-site, double-blind, placebo-controlled, fixed-dose investigation. Br J Psychiatry 173:54–60, 1998
[PubMed]
 
Londborg PD, Hegel MT, Goldstein S, et al: Sertraline treatment of posttraumatic stress disorder: results of 24 weeks of open-label continuation treatment. J Clin Psychiatry 62:325–331, 2001
[PubMed]
 
Lott M, Greist JH, Jefferson JW, et al: Brofaromine for social phobia: a multicenter, placebo-controlled, double-blind study. J Clin Psychopharmacol 17:255–260, 1997
[PubMed]
 
Lydiard RB, Ballenger JC: Antidepressants in panic disorder and agoraphobia. J Affect Disord 13:153–168, 1987
[PubMed]
 
Lydiard RB, Laraia MT, Ballenger JC, et al: Emergence of depressive symptoms in patients receiving alprazolam for panic disorder. Am J Psychiatry 144:664–665, 1987
[PubMed]
 
Lydiard RB, Lesser IM, Ballenger JC, et al: A fixed-dose study of alprazolam 2 mg, alprazolam 6 mg, and placebo in panic disorder. J Clin Psychopharmacol 12:96–103, 1992
[PubMed]
 
Lydiard RB, Morton WA, Emmanuel NP, et al: Preliminary report: placebo-controlled, double-blind study of the clinical and metabolic effects of desipramine in panic disorder. Psychopharmacol Bull 29:183–188, 1993
[PubMed]
 
Lydiard RB, Steiner M, Burnham D, et al: Efficacy studies of paroxetine in panic disorder. Psychopharmacol Bull 34:175–182, 1998
[PubMed]
 
Magee WJ, Eaton WW, Wittchen HU, et al: Agoraphobia, simple phobia, and social phobia in the National Comorbidity Survey. Arch Gen Psychiatry 53:159–168, 1996
[PubMed]
 
March JS, Biederman J, Wolkow R, et al: Sertraline in children and adolescents with obsessive-compulsive disorder: a multicenter randomized controlled trial. JAMA 280:1752–1756, 1998
[PubMed]
 
March JS, Entsuah AR, Rynn M, et al: A randomized controlled trial of venlafaxine ER versus placebo in pediatric social anxiety disorder. Biol Psychiatry 62:1149–1154, 2007
[PubMed]
 
Marks IM, Mathews AM: Brief standard self-rating for phobic patients. Behav Res Ther 17:263–267, 1979
[PubMed]
 
Marmar CR, Schoenfeld F, Weiss DS, et al: Open trial of fluvoxamine treatment for combat-related posttraumatic stress disorder. J Clin Psychiatry 57 (suppl 8):66–70, 1996
 
Marshall RD, Beebe KL, Oldham M, et al: Efficacy and safety of paroxetine treatment for chronic PTSD: a fixed-dose, placebo-controlled study. Am J Psychiatry 158:1982–1988, 2001
[PubMed]
 
Martenyi F, Brown EB, Zhang H, et al: Fluoxetine versus placebo in posttraumatic stress disorder. J Clin Psychiatry 63:199–206, 2002a
 
Martenyi F, Brown EB, Zhang H, et al: Fluoxetine vs placebo in prevention of relapse in post-traumatic stress disorder. Br J Psychiatry 181:315–320, 2002b
 
Mathew SJ, Ho S: Etiology and neurobiology of social anxiety disorder. J Clin Psychiatry 67 (suppl 12):9–13, 2007
 
Mathew SJ, Amiel JM, Coplan JD, et al: Open-label trial of riluzole in generalized anxiety disorder. Am J Psychiatry 162:2379–2381, 2005
[PubMed]
 
Mavissakalian MR, Perel JM: Imipramine dose-response relationship in panic disorder with agoraphobia. Preliminary findings. Arch Gen Psychiatry 46:127–131, 1989
[PubMed]
 
Mavissakalian M, Perel JM: Protective effects of imipramine maintenance treatment in panic disorder with agoraphobia. Am J Psychiatry 149:1053–1057, 1992
[PubMed]
 
Mavissakalian MR, Perel JM: Imipramine treatment of panic disorder with agoraphobia: dose ranging and plasma level-response relationships. Am J Psychiatry 152:673–682, 1995
[PubMed]
 
Mavissakalian MR, Perel JM: Duration of imipramine therapy and relapse in panic disorder with agoraphobia. J Clin Psychopharmacol 22:294–299, 2002
[PubMed]
 
Mavissakalian MR, Jones B, Olson S: Absence of placebo response in obsessive-compulsive disorder. J Nerv Ment Dis 178:268–270, 1990
[PubMed]
 
Mellman TA, Bustamante V, David D, et al: Hypnotic medication in the aftermath of trauma. J Clin Psychiatry 63:1183–1184, 2002
[PubMed]
 
Mellman TA, Clark RE, Peacock WJ: Prescribing patterns for patients with posttraumatic stress disorder. Psychiatr Serv 54:1618–1621, 2003
[PubMed]
 
Meoni P, Hackett D: Characterization of the longitudinal course of long-term venlafaxine-ER treatment of GAD. Paper presented at the 13th Annual Meeting of the European College of Neuropsychopharmacology, Munich, Germany, September 11, 2000
 
Michelson D, Lydiard RB, Pollack MH, et al: Outcome assessment and clinical improvement in panic disorder: evidence from a randomized controlled trial of fluoxetine and placebo. The Fluoxetine Panic Disorder Study Group. Am J Psychiatry 155:1570–1577, 1998
[PubMed]
 
Michelson D, Pollack M, Lydiard RB, et al: Continuing treatment of panic disorder after acute response: randomised, placebo-controlled trial with fluoxetine. The Fluoxetine Panic Disorder Study Group. Br J Psychiatry 174:213–218, 1999
[PubMed]
 
Michelson D, Allgulander C, Dantendorfer K, et al: Efficacy of usual antidepressant dosing regimens of fluoxetine in panic disorder: randomised, placebo-controlled trial. Br J Psychiatry 179:514–518, 2001
[PubMed]
 
Modigh K, Westberg P, Eriksson E: Superiority of clomipramine over imipramine in the treatment of panic disorder: a placebo-controlled trial. J Clin Psychopharmacol 12:251–261, 1992
[PubMed]
 
Monnelly EP, Ciraulo DA, Knapp C, et al: Low-dose risperidone as adjunctive therapy for irritable aggression in posttraumatic stress disorder. J Clin Psychopharmacol 23:193–196, 2003
[PubMed]
 
Montgomery SA, Nil R, Durr-Pal N, et al: A 24-week randomized, double-blind, placebo-controlled study of escitalopram for the prevention of generalized social anxiety disorder. J Clin Psychiatry 66:1270–1278, 2005
[PubMed]
 
Moras K, Borkovec TD, DiNardo PA, et al: Generalized anxiety disorder, in DSM-IV Sourcebook. Edited by Widiger TA, Frances AJ, Pincus HA, et al. Washington, DC, American Psychiatric Association, 1996, pp 607–621
 
Muehlbacher M, Nickel MK, Nickel C, et al: Mirtazapine treatment of social phobia in women: a randomized, double-blind, placebo controlled trial. J Clin Psychopharmacol 25:580–583, 2005
[PubMed]
 
Murray CJL, Lopez AD: The Global Burden of Disease. Cambridge, MA, Harvard School of Public Health, 1996
 
Myers JK, Weissman MM, Tischler GL, et al: Six-month prevalence of psychiatric disorders in three communities 1980 to 1982. Arch Gen Psychiatry 41:959–967, 1984
[PubMed]
 
Neal LA, Shapland W, Fox C: An open trial of moclobemide in the treatment of post-traumatic stress disorder. Int Clin Psychopharmacol 12:231–237, 1997
[PubMed]
 
Neylan TC, Lenoci M, Samuelson KW, et al: No improvement of posttraumatic stress disorder symptoms with guanfacine treatment. Am J Psychiatry 163:2186–2188, 2006
[PubMed]
 
Ninan PT, Koran LM, Kiev A, et al: High-dose sertraline strategy for nonresponders to acute treatment for obsessive-compulsive disorder: a multicenter double-blind trial. J Clin Psychiatry 67:15–22, 2006
[PubMed]
 
Noyes R Jr, Moroz G, Davidson JR, et al: Moclobemide in social phobia: a controlled dose-response trial. J Clin Psychopharmacol 17:247–254, 1997
[PubMed]
 
Nuttin B, Cosyns P, Demeulemeester H, et al: Electrical stimulation in anterior limbs of internal capsules in patients with obsessive-compulsive disorder. Lancet 354:1526, 1999
[PubMed]
 
Oehrberg S, Christiansen PE, Behnke K, et al: Paroxetine in the treatment of panic disorder. A randomised, double-blind, placebo-controlled study. Br J Psychiatry 167:374–379, 1995
[PubMed]
 
Olajide D, Lader M: A comparison of buspirone, diazepam, and placebo in patients with chronic anxiety states. J Clin Psychopharmacol 7:148–152, 1987
[PubMed]
 
Otto MW, Pollack MH, Sachs GS, et al: Discontinuation of benzodiazepine treatment: efficacy of cognitive-behavioral therapy for patients with panic disorder. Am J Psychiatry 150:1485–1490, 1993
[PubMed]
 
Otto MW, Tuby KS, Gould RA, et al: An effect-size analysis of the relative efficacy and tolerability of serotonin selective reuptake inhibitors for panic disorder. Am J Psychiatry 158:1989–1992, 2001
[PubMed]
 
Pages KP, Ries RK: Use of anticonvulsants in benzodiazepine withdrawal. Am J Addict 7:198–204, 1998
[PubMed]
 
Pande AC, Davidson JR, Jefferson JW, et al: Treatment of social phobia with gabapentin: a placebo-controlled study. J Clin Psychopharmacol 19:341–348, 1999a
 
Pande AC, Greiner M, Adams JB, et al: Placebo-controlled trial of the CCK-B antagonist, CI-988, in panic disorder. Biol Psychiatry 46:860–862, 1999b
 
Pande AC, Pollack MH, Crockatt J, et al: Placebo-controlled study of gabapentin treatment of panic disorder. J Clin Psychopharmacol 20:467–471, 2000
[PubMed]
 
Pande AC, Crockatt JG, Feltner DE, et al: Pregabalin in generalized anxiety disorder: a placebo-controlled trial. Am J Psychiatry 160:533–540, 2003
[PubMed]
 
Papp LA: Safety and efficacy of levetiracetam for patients with panic disorder: results of an open-label, fixed-flexible dose study. J Clin Psychiatry 67:1573–1576, 2006
[PubMed]
 
Pato MT, Hill JL, Murphy DL: A clomipramine dosage reduction study in the course of long-term treatment of obsessive-compulsive disorder patients. Psychopharmacol Bull 26:211–214, 1990
[PubMed]
 
Pecknold J, Luthe L, Munjack D, et al: A double-blind, placebo-controlled, multicenter study with alprazolam and extended-release alprazolam in the treatment of panic disorder. J Clin Psychopharmacol 14:314–321, 1994
[PubMed]
 
Petracca A, Nisita C, McNair D, et al: Treatment of generalized anxiety disorder: preliminary clinical experience with buspirone. J Clin Psychiatry 51 (suppl):31–39, 1990
 
Pigott T, L'Hereux F, Rubinstein CS: A controlled trial of clonazepam augmentation in OCD patients with clomipramine or fluoxetine (NR82). Paper presented at the 145th Annual Meeting of the American Psychiatric Association, May 2–7, 1992
 
Pitman RK, Sanders KM, Zusman RM, et al: Pilot study of secondary prevention of posttraumatic stress disorder with propranolol. Biol Psychiatry 51:189–192, 2002
[PubMed]
 
Pohl RB, Feltner DE, Fieve RR, et al: Efficacy of pregabalin in the treatment of generalized anxiety disorder: double-blind, placebo-controlled comparison of BID versus TID dosing. J Clin Psychopharmacol 25:151–158, 2005
[PubMed]
 
Pollack MH, Zaninelli R, Goddard A, et al: Paroxetine in the treatment of generalized anxiety disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:350–357, 2001
[PubMed]
 
Pollack MH, Simon NM, Worthington JJ, et al: Combined paroxetine and clonazepam treatment strategies compared to paroxetine monotherapy for panic disorder. J Psychopharmacol (Oxf) 17:276–282, 2003
[PubMed]
 
Pollack MH, Roy-Byrne PP, Van Ameringen M, et al: The selective GABA reuptake inhibitor tiagabine for the treatment of generalized anxiety disorder: results of a placebo-controlled study. J Clin Psychiatry 66:1401–1408, 2005
[PubMed]
 
Rapaport MH, Wolkow R, Rubin A, et al: Sertraline treatment of panic disorder: results of a long-term study. Acta Psychiatr Scand 104:289–298, 2001
[PubMed]
 
Rapaport MH, Endicott J, Clary CM: Posttraumatic stress disorder and quality of life: results across 64 weeks of sertraline treatment. J Clin Psychiatry 63:59–65, 2002
[PubMed]
 
Raskind MA, Peskind ER, Kanter ED, et al: Reduction of nightmares and other PTSD symptoms in combat veterans by prazosin: a placebo-controlled study. Am J Psychiatry 160:371–373, 2003
[PubMed]
 
Raskind MA, Peskind ER, Hoff DJ, et al: A parallel group placebo controlled study of prazosin for trauma nightmares and sleep disturbance in combat veterans with post-traumatic stress disorder. Biol Psychiatry 61:928–934, 2007
[PubMed]
 
Ravizza L, Barzega G, Bellino S, et al: Drug treatment of obsessive-compulsive disorder (OCD): long-term trial with clomipramine and selective serotonin reuptake inhibitors (SSRIs). Psychopharmacol Bull 32:167–173, 1996
[PubMed]
 
Reich DB, Winternitz S, Hennen J, et al: A preliminary study of risperidone in the treatment of posttraumatic stress disorder related to childhood abuse in women. J Clin Psychiatry 65:1601–1606, 2004
[PubMed]
 
Research Unit on Pediatric Psychopharmacology Anxiety Study Group: Fluvoxamine for the treatment of anxiety disorders in children and adolescents. N Engl J Med 344:1279–1285, 2001
 
Ressler KJ, Rothbaum BO, Tannenbaum L, et al: Cognitive enhancers as adjuncts to psychotherapy: use of D-cycloserine in phobic individuals to facilitate extinction of fear. Arch Gen Psychiatry 61:1136–1144, 2004
[PubMed]
 
Ribeiro L, Busnello JV, Kauer-Sant'Anna M, et al: Mirtazapine versus fluoxetine in the treatment of panic disorder. Braz J Med Biol Res 34:1303–1307, 2001
[PubMed]
 
Rickels K, Weisman K, Norstad N, et al: Buspirone and diazepam in anxiety: a controlled study. J Clin Psychiatry 43:81–86, 1982
[PubMed]
 
Rickels K, Case WG, Downing RW, et al: Long-term diazepam therapy and clinical outcome. JAMA 250:767–771, 1983
[PubMed]
 
Rickels K, Fox IL, Greenblatt DJ, et al: Clorazepate and lorazepam: clinical improvement and rebound anxiety. Am J Psychiatry 145:312–317, 1988a
 
Rickels K, Schweizer E, Csanalosi I, et al: Long-term treatment of anxiety and risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 45:444–450, 1988b
 
Rickels K, Amsterdam JD, Clary C, et al: Buspirone in major depression: a controlled study. J Clin Psychiatry 52:34–38, 1991
[PubMed]
 
Rickels K, Downing R, Schweizer E, et al: Antidepressants for the treatment of generalized anxiety disorder. A placebo-controlled comparison of imipramine, trazodone, and diazepam. Arch Gen Psychiatry 50:884–895, 1993
[PubMed]
 
Rickels K, DeMartinis N, Garcia-Espana F, et al: Imipramine and buspirone in treatment of patients with generalized anxiety disorder who are discontinuing long-term benzodiazepine therapy. Am J Psychiatry 157:1973–1979, 2000a
 
Rickels K, Pollack MH, Sheehan DV, et al: Efficacy of extended-release venlafaxine in nondepressed outpatients with generalized anxiety disorder. Am J Psychiatry 157:968–974, 2000b
 
Rickels K, Zaninelli R, McCafferty J, et al: Paroxetine treatment of generalized anxiety disorder: a double-blind, placebo-controlled study. Am J Psychiatry 160:749–756, 2003
[PubMed]
 
Rickels K, Pollack MH, Feltner DE, et al: Pregabalin for treatment of generalized anxiety disorder: a 4-week, multicenter, double-blind, placebo-controlled trial of pregabalin and alprazolam. Arch Gen Psychiatry 62:1022–1030, 2005
[PubMed]
 
Riddle MA, Reeve EA, Yaryura-Tobias JA, et al: Fluvoxamine for children and adolescents with obsessive-compulsive disorder: a randomized, controlled, multicenter trial. J Am Acad Child Adolesc Psychiatry 40:222–229, 2001
[PubMed]
 
Robert R, Blakeney PE, Villarreal C, et al: Imipramine treatment in pediatric burn patients with symptoms of acute stress disorder: a pilot study. J Am Acad Child Adolesc Psychiatry 38:873–882, 1999a
 
Robert R, Meyer WJ 3rd, Villarreal C, et al: An approach to the timely treatment of acute stress disorder. J Burn Care Rehabil 20:250–258, 1999b
 
Robins LN, Helzer JE, Weissman MM, et al: Lifetime prevalence of specific psychiatric disorders in three sites. Arch Gen Psychiatry 41:949–958, 1984
[PubMed]
 
Rocca P, Fonzo V, Scotta M, et al: Paroxetine efficacy in the treatment of generalized anxiety disorder. Acta Psychiatr Scand 95:444–450, 1997
[PubMed]
 
Rosenbaum JF, Woods SW, Groves JE, et al: Emergence of hostility during alprazolam treatment. Am J Psychiatry 141:792–793, 1984
[PubMed]
 
Rosenbaum JF, Moroz G, Bowden CL: Clonazepam in the treatment of panic disorder with or without agoraphobia: a dose-response study of efficacy, safety, and discontinuance. Clonazepam Panic Disorder Dose-Response Study Group. J Clin Psychopharmacol 17:390–400, 1997
[PubMed]
 
Ross CA, Matas M: A clinical trial of buspirone and diazepam in the treatment of generalized anxiety disorder. Can J Psychiatry 32:351–355, 1987
[PubMed]
 
Royal Australian and New Zealand College of Psychiatrists Clinical Practice Guidelines Team for Panic Disorder and Agoraphobia: Australian and New Zealand clinical practice guidelines for the treatment of panic disorder and agoraphobia. Aust N Z J Psychiatry 37:641–656, 2003
 
Roy-Byrne PP, Stang P, Wittchen HU, et al: Lifetime panic-depression comorbidity in the National Comorbidity Survey. Association with symptoms, impairment, course and help-seeking. Br J Psychiatry 176:229–235, 2000
[PubMed]
 
Roy-Byrne PP, Clary CM, Miceli RJ, et al: The effect of selective serotonin reuptake inhibitor treatment of panic disorder on emergency room and laboratory resource utilization. J Clin Psychiatry 62:678–682, 2001
[PubMed]
 
Rynn M, Russell JM, Erickson J, et al: Efficacy and safety of duloxetine in the treatment of generalized anxiety disorder: a flexible-dose, progressive-titration, placebo-controlled trial. Depress Anxiety 25:182–189, 2008
[PubMed]
 
Sarchiapone M, Amore M, De Risio S, et al: Mirtazapine in the treatment of panic disorder: an open-label trial. Int Clin Psychopharmacol 18:35–38, 2003
[PubMed]
 
Schelling G, Roozendaal B, Krauseneck T, et al: Efficacy of hydrocortisone in preventing posttraumatic stress disorder following critical illness and major surgery. Ann N Y Acad Sci 1071:46–53, 2006
[PubMed]
 
Schneier FR, Goetz D, Campeas R, et al: Placebo-controlled trial of moclobemide in social phobia. Br J Psychiatry 172:70–77, 1998
[PubMed]
 
Schweizer E, Rickels K: Buspirone in the treatment of panic disorder: a controlled pilot comparison with clorazepate. J Clin Psychopharmacol 8:303, 1988
[PubMed]
 
Schweizer E, Rickels K: Pharmacological treatment for generalized anxiety disorder, in Long-term Treatments of Anxiety Disorders. Edited by Mavissakalian M, Prien RF. Washington, DC, American Psychiatric Press, 1996, pp 201–220
 
Schweizer E, Rickels K, Lucki I: Resistance to the anti-anxiety effect of buspirone in patients with a history of benzodiazepine use. N Engl J Med 314:719–720, 1986
[PubMed]
 
Schweizer E, Patterson W, Rickels K, et al: Double-blind, placebo-controlled study of a once-a-day, sustained-release preparation of alprazolam for the treatment of panic disorder. Am J Psychiatry 150:1210–1215, 1993
[PubMed]
 
Sepede G, De Berardis D, Gambi F, et al: Olanzapine augmentation in treatment-resistant panic disorder: a 12-week, fixed-dose, open-label trial. J Clin Psychopharmacol 26:45–49, 2006
[PubMed]
 
Shader RI, Greenblatt DJ: Use of benzodiazepines in anxiety disorders. N Engl J Med 328:1398–1405, 1993
[PubMed]
 
Shear MK, Brown TA, Barlow DH, et al: Multicenter collaborative panic disorder severity scale. Am J Psychiatry 154:1571–1575, 1997
[PubMed]
 
Sheehan DV: The Anxiety Disease. Bantam Books, New York, 1986
 
Sheehan DV, Ballenger J, Jacobsen G: Treatment of endogenous anxiety with phobic, hysterical, and hypochondriacal symptoms. Arch Gen Psychiatry 37:51–59, 1980
[PubMed]
 
Sheehan DV, Davidson J, Manschreck T, et al: Lack of efficacy of a new antidepressant (bupropion) in the treatment of panic disorder with phobias. J Clin Psychopharmacol 3:28–31, 1983
[PubMed]
 
Sheehan DV, Raj AB, Sheehan KH, et al: Is buspirone effective for panic disorder? J Clin Psychopharmacol 10:3–11, 1990
[PubMed]
 
Sheehan DV, Burnham DB, Iyengar MK, et al: Efficacy and tolerability of controlled-release paroxetine in the treatment of panic disorder. J Clin Psychiatry 66:34–40, 2005
[PubMed]
 
Silverstone PH, Salinas E: Efficacy of venlafaxine extended release in patients with major depressive disorder and comorbid generalized anxiety disorder. J Clin Psychiatry 62:523–529, 2001
[PubMed]
 
Simon NM, Emmanuel N, Ballenger J, et al: Bupropion sustained release for panic disorder. Psychopharmacol Bull 37:66–72, 2003
[PubMed]
 
Simon NM, Hoge EA, Fischmann D, et al: An open-label trial of risperidone augmentation for refractory anxiety disorders. J Clin Psychiatry 67:381–385, 2006
[PubMed]
 
Simpson HB, Schneier FR, Marshall RD, et al: Low dose selegiline (L-deprenyl) in social phobia. Depress Anxiety 7:126–129, 1998
[PubMed]
 
Snyderman SH, Rynn MA, Rickels K: Open-label pilot study of ziprasidone for refractory generalized anxiety disorder. J Clin Psychopharmacol 25:497–499, 2005
[PubMed]
 
Stahl SM, Gergel I, Li D: Escitalopram in the treatment of panic disorder: a randomized, double-blind, placebo-controlled trial. J Clin Psychiatry 64:1322–1327, 2003
[PubMed]
 
Stein DJ, Andersen EW, Tonnoir B, et al: Escitalopram in obsessive-compulsive disorder: a randomized, placebo-controlled, paroxetine-referenced, fixed-dose, 24-week study. Curr Med Res Opin 23:701–711, 2007
[PubMed]
 
Stein MB, Chartier MJ, Hazen AL, et al: Paroxetine in the treatment of generalized social phobia: open-label treatment and double-blind placebo-controlled discontinuation. J Clin Psychopharmacol 16:218–222, 1996
[PubMed]
 
Stein MB, Liebowitz MR, Lydiard RB, et al: Paroxetine treatment of generalized social phobia (social anxiety disorder): a randomized controlled trial. JAMA 280:708–713, 1998
[PubMed]
 
Stein MB, Fyer AJ, Davidson JR, et al: Fluvoxamine treatment of social phobia (social anxiety disorder): a double-blind, placebo-controlled study. Am J Psychiatry 156:756–760, 1999
[PubMed]
 
Stein MB, Kline NA, Matloff JL: Adjunctive olanzapine for SSRI-resistant combat-related PTSD: a double-blind, placebo-controlled study. Am J Psychiatry 159:1777–1779, 2002
[PubMed]
 
Stein MB, Seedat S, Gelernter J: Serotonin transporter gene promoter polymorphism predicts SSRI response in generalized social anxiety disorder. Psychopharmacology (Berl) 187:168–172, 2006
 
Stinson FS, Dawson DA, Patricia Chou S, et al: The epidemiology of DSM-IV specific phobia in the USA: results from the National Epidemiologic Survey on Alcohol and Related Conditions. Psychol Med 37:1047–1059, 2007
[PubMed]
 
Strand M, Hetta J, Rosen A, et al: A double-blind, controlled trial in primary care patients with generalized anxiety: a comparison between buspirone and oxazepam. J Clin Psychiatry 51 (suppl):40–45, 1990
 
Sutherland SM, Tupler LA, Colket JT, et al: A 2-year follow-up of social phobia. Status after a brief medication trial. J Nerv Ment Dis 184:731–738, 1996
[PubMed]
 
Swinson RP, Antony MM, Bleau P, et al: Clinical practice guidelines. Management of anxiety disorders. Can J Psychiatry 51 (suppl 2):1–92, 2006
 
Szegedi A, Wetzel H, Leal M, et al: Combination treatment with clomipramine and fluvoxamine: drug monitoring, safety, and tolerability data. J Clin Psychiatry 57:257–264, 1996
[PubMed]
 
Taylor LH, Kobak KA: An open-label trial of St John's wort (Hypericum perforatum) in obsessive-compulsive disorder. J Clin Psychiatry 61:575–578, 2000
[PubMed]
 
Tesar GE, Rosenbaum JF, Pollack MH, et al: Double-blind, placebo-controlled comparison of clonazepam and alprazolam for panic disorder. J Clin Psychiatry 52:69–76, 1991
[PubMed]
 
Thoren P, Asberg M, Cronholm B, et al: Clomipramine treatment of obsessive-compulsive disorder, I: a controlled clinical trial. Arch Gen Psychiatry 37:1281–1285, 1980
[PubMed]
 
Tiller JW, Bouwer C, Behnke K: Moclobemide and fluoxetine for panic disorder. International Panic Disorder Study Group. Eur Arch Psychiatry Clin Neurosci 249 (suppl 1):S7–S10, 1999
 
Tollefson GD, Rampey AH Jr, Potvin JH, et al: A multicenter investigation of fixed-dose fluoxetine in the treatment of obsessive-compulsive disorder. Arch Gen Psychiatry 51:559–567, 1994
[PubMed]
 
True WR, Rice J, Eisen SA, et al: A twin study of genetic and environmental contributions to liability for posttraumatic stress symptoms. Arch Gen Psychiatry 50:257–264, 1993
[PubMed]
 
Tucker P, Smith KL, Marx B, et al: Fluvoxamine reduces physiologic reactivity to trauma scripts in posttraumatic stress disorder. J Clin Psychopharmacol 20:367–372, 2000
[PubMed]
 
Tucker P, Zaninelli R, Yehuda R, et al: Paroxetine in the treatment of chronic posttraumatic stress disorder: results of a placebo-controlled, flexible-dosage trial. J Clin Psychiatry 62:860–868, 2001
[PubMed]
 
Turner SM, Beidel DC, Jacob RG: Social phobia: a comparison of behavior therapy and atenolol. J Consult Clin Psychol 62:350–358, 1994
[PubMed]
 
Van Ameringen M, Mancini C, Oakman JM: Nefazodone in social phobia. J Clin Psychiatry 60:96–100, 1999
 
Van Ameringen MA, Lane RM, Walker JR, et al: Sertraline treatment of generalized social phobia: a 20-week, double-blind, placebo-controlled study. Am J Psychiatry 158:275–281, 2001
 
Van Ameringen M, Mancini C, Oakman J, et al: Nefazodone in the treatment of generalized social phobia: a randomized, placebo-controlled trial. J Clin Psychiatry 68:288–295, 2007
 
van der Kolk BA, Dreyfuss D, Michaels M, et al: Fluoxetine in posttraumatic stress disorder [see comment]. J Clin Psychiatry 55:517–522, 1994
 
van Vliet IM, den Boer JA, Westenberg HG: Psychopharmacological treatment of social phobia: clinical and biochemical effects of brofaromine, a selective MAO-A inhibitor. Eur Neuropsychopharmacol 2:21–29, 1992
 
van Vliet IM, den Boer JA, Westenberg HG: Psychopharmacological treatment of social phobia: a double blind placebo controlled study with fluvoxamine. Psychopharmacology (Berl) 115:128–134, 1994
 
van Vliet IM, den Boer JA, Westenberg HG, et al: Clinical effects of buspirone in social phobia: a double-blind placebo-controlled study. J Clin Psychiatry 58:164–168, 1997
 
Versiani M, Nardi AE, Mundim FD, et al: Pharmacotherapy of social phobia. A controlled study with moclobemide and phenelzine. Br J Psychiatry 161:353–360, 1992
[PubMed]
 
Versiani M, Nardi AE, Figueria J: Double-blind placebo-controlled trial with bromazepam in social phobia. J Bras Psiquitr 46:167–171, 1997
 
Versiani M, Cassano G, Perugi G, et al: Reboxetine, a selective norepinephrine reuptake inhibitor, is an effective and well-tolerated treatment for panic disorder. J Clin Psychiatry 63:31–37, 2002
[PubMed]
 
Wade AG, Lepola U, Koponen HJ, et al: The effect of citalopram in panic disorder. Br J Psychiatry 170:549–553, 1997
[PubMed]
 
Wagner KD, Berard R, Stein MB, et al: A multicenter, randomized, double-blind, placebo-controlled trial of paroxetine in children and adolescents with social anxiety disorder. Arch Gen Psychiatry 61:1153–1162, 2004
[PubMed]
 
Walker JR, Van Ameringen MA, Swinson R, et al: Prevention of relapse in generalized social phobia: results of a 24-week study in responders to 20 weeks of sertraline treatment. J Clin Psychopharmacol 20:636–644, 2000
[PubMed]
 
Weathers FW, Keane TM, Davidson JRT: Clinician-administered PTSD scale: a review of the first ten years of research. Depress Anxiety 13:132–156, 2001
[PubMed]
 
Westenberg HG, Stein DJ, Yang H, et al: A double-blind placebo-controlled study of controlled release fluvoxamine for the treatment of generalized social anxiety disorder. J Clin Psychopharmacol 24:49–55, 2004
[PubMed]
 
Westenberg HG, Fineberg N, Denys D: Neurobiology of obsessive-compulsive disorder: serotonin and beyond. CNS Spectr 12 (suppl 3):14–27, 2007
 
Williams JE, Nieto FJ, Sanford CP, et al: Effects of an angry temperament on coronary heart disease risk: the Atherosclerosis Risk in Communities Study. Am J Epidemiol 154:230–235, 2001
[PubMed]
 
Wittchen HU, Hoyer J: Generalized anxiety disorder: nature and course. J Clin Psychiatry 62 (suppl 11):15–19, 2001
 
Wittchen HU, Zhao S, Kessler RC, et al: DSM-III-R generalized anxiety disorder in the National Comorbidity Survey. Arch Gen Psychiatry 51:355–364, 1994
[PubMed]
 
Wurthmann C, Klieser E, Lehmann E: [Differential pharmacologic therapy of generalized anxiety disorders—results of a study with 30 individual case experiments]. Fortschritte der Neurologie-Psychiatrie 63:303–309, 1995
[PubMed]
 
Zigmond AS, Snaith RP: The Hospital Anxiety and Depression Scale. Acta Psychiatr Scand 67:361–370, 1983
[PubMed]
 
Zimmerman M, Mattia JI: Principal and additional DSM-IV disorders for which outpatients seek treatment. Psychiatr Serv 51:1299–1304, 2000
[PubMed]
 
Zitrin CM, Klein DF, Woerner MG, et al: Treatment of phobias, I: comparison of imipramine hydrochloride and placebo. Arch Gen Psychiatry 40:125–138, 1983
[PubMed]
 
Zohar J, Amital D, Miodownik C, et al: Double-blind placebo-controlled pilot study of sertraline in military veterans with posttraumatic stress disorder. J Clin Psychopharmacol 22:190–195, 2002
[PubMed]
 
Zwanzger P, Baghai TC, Schule C, et al: Tiagabine improves panic and agoraphobia in panic disorder patients. J Clin Psychiatry 62:656–657, 2001
[PubMed]
 
+

CME Activity

Add a subscription to complete this activity and earn CME credit.
Sample questions:
1.
Which of the following medications has been approved by the U.S. Food and Drug Administration (FDA) to treat obsessive-compulsive disorder (OCD) in adults but not in children?
2.
A patient with severe symptoms of OCD has demonstrated a partial response to a selective serotonin reuptake inhibitor (SSRI). You decide to add another agent to the SSRI. In reviewing the literature, you conclude that the augmentation agent most likely to produce a beneficial result is
3.
You are treating a 72-year-old woman with panic disorder. A good first-line medication choice for this patient would be
NOTE:
Citing articles are presented as examples only. In non-demo SCM6 implementation, integration with CrossRef’s "Cited By" API will populate this tab (http://www.crossref.org/citedby.html).
Related Content
Articles
Books
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 3.  >
Manual of Clinical Psychopharmacology, 7th Edition > Chapter 6.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 12.  >
The American Psychiatric Publishing Textbook of Psychiatry, 5th Edition > Chapter 26.  >
Gabbard's Treatments of Psychiatric Disorders, 4th Edition > Chapter 2.  >
Topic Collections
Psychiatric News
PubMed Articles
 
  • Print
  • PDF
  • E-mail
  • Chapter Alerts
  • Get Citation